A Phase II, Placebo Controlled, Clinical Trial of Topical TolaSure Targeting Aggregated Mutant Keratin in Epidermolysis Bullosa Simplex

NCT07027345 | Recruiting Phase 2 FDA Drug

• 1 other identifier: TAMES-02
• Study Type: interventional
• Target: 40
• Locations: 1 country
• Sites: 2

Brief Summary

This Phase II clinical study will assess the efficacy, safety and tolerability of topical TolaSure Gel in adults and pediatric patients (2 years of age and older) diagnosed with localized, intermediate, or severe epidermolysis bullosa simplex (EBS). Each patient (40 to complete) will be enrolled in the study and will be randomized to receive either TolaSure Gel or a topical Placebo for daily application for 2-months. After 2-months, all patients will receive TolaSure Gel to daily apply for an additional 2-months. A remote follow-up visit will occur 2-months after the end of study. Total time in the study is 6-months. Localized patients will be applying study medication to their feet, with the option to treat their hands as well throughout the study. Intermediate and severe EBS patients will be applying study medication to randomized treatment area(s) (a minimum of \~2-3% Body Surface Area (BSA)), with the option to treat their feet as well throughout the study.

Conditions

Epidermolysis Bullosa Simplex

Keywords

Epidermolysis Bullosa; Epidermolysis Bullosa Simplex; EBS; Severe EBS; EBS Dowling-Meara; EBS Koebner; Skin Diseases; Keratin; Aggregate; Mutant; EBS-DM; Keratin Disorder; Skin Abnormalities; generalized; intermediate

Outcome Measures

Primary Outcomes (1)

• Change in Blister Surface Area of the Designated Treatment Area(s)

  Clinical photography will be used to assess changes in disease severity within the target lesional area (TLA) and recurrence of blistering by measuring blister surface area in the designated TLA over time.

  Day 1 (Baseline) and weekly until End of Study (2-months and maximum 4-months)

Secondary Outcomes (6)

• Plantar Blister Surface Area Reduction

  Day 1 (Baseline) and weekly until End of Study (2-months and maximum 4-months)

• Subject-reported Pain Score in Target Lesional Areas During Treatment Application

  Day 1 (Baseline) and weekly until End of Study (2-months and maximum 4-months)

• Subject-reported Itch Score in Target Lesional Area

  Day 1 (Baseline) and weekly until End of Study (2-months and maximum 4-months)

• Subject-reported Quality of Life (QoL)

  Day 1 (Baseline), Part 1 End of Study (2-months), Part 2 End of Study (4-months)

• Subject-reported Modified Foot Function Index (mFFI)

  Day 1 (Baseline), Part 1 End of Study (2-months), Part 2 End of Study (4-months)

Other Outcomes (1)

• Blistering and Keratoderma of Hands

  Day 1 (Baseline) and weekly until End of Study (2-months and maximum 4-months)

Study Arms (2)

5% TolaSure Topical Gel

ACTIVE COMPARATOR

5% (w/w) TolaSure Gel

Drug: 5% TolaSure Topical Gel

Topical Placebo Gel

PLACEBO COMPARATOR

Placebo Control Gel

Drug: Topical Placebo Gel

Interventions

5% TolaSure Topical Gel DRUG

TolaSure Topical Gel is applied once-daily to designated treatment areas for up to 4 months (Part 2 End of Study).

5% TolaSure Topical Gel

Topical Placebo Gel DRUG

Topical Placebo Gel is applied once-daily to designated treatment areas for up to 2 months (Part 1 End of Study).

Topical Placebo Gel

Eligibility Criteria

• Age: 2 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)

You may qualify if:

• Patient is a male or female at least 2 years of age.
• Patient has a documented diagnosis and confirmed clinical history of localized (previously known as Weber-Cockayne), intermediate (previously Kӧbner), or severe (previously EBS-Dowling Meara) autosomal dominant EBS and/or a genetic mutation in either the KRT14 or KRT5 gene consistent with localized, intermediate, or severe EBS. The Investigator will determine patient eligibility based on historical phenotypic presentation of EBS symptoms along with genetic/diagnosis documentation to determine EBS severity. (If localized, intermediate, or severe EBS is suspected but not diagnosed or genetically confirmed, confirmatory testing will be performed).
• For localized EBS participants:
• Patient must have at least moderate plantar disease activity, defined as ≥15% involvement of the plantar surface of at least one foot, as assessed by clinical examination or standardized imaging, with evidence of active disease (e.g., blisters, erosions, or crusting).
• For treatment, the Target Lesional Area (TLA) will consist of daily treating the feet (tops and bottoms) which is approximately 7% body surface area (BSA). Localized EBS subjects will also have the option to treat their hands (tops and bottoms), which is approximately an additional 6% BSA. Palmoplantar evaluation is separate from the intermediate to severe TLA-treated regions per protocol.
• For intermediate to severe EBS participants: Patient is actively flaring in one of the preferred target lesional areas (TLAs): 1) lower extremities (ideally below the knee and above the ankle or between the knee and top of the thigh) or 2) torso (excluding the groin and apocrine areas). The following skin conditions are required for treatment purposes:
• A TLA is defined as a contiguous or non-contiguous region totaling up to \~15-20% body surface area (BSA).
• A flare is defined as a minimum area of \~2-3% Body Surface Area (BSA) containing intact blisters (of varying size and number), and freshly ruptured blisters across 50% of the TLA (as assessed by the principal investigator (PI)). Skin erosions, keratoderma, fissures and/or erythema may also be present.
• For all patients (with localized, intermediate, and severe EBS), the TLA may not be infected (as assessed by PI) or have been treated with a topical antibiotic within 14 days.
• If the patient is a woman of childbearing potential (WOCBP),
• Has a negative urine pregnancy test.
• Agrees to use an approved effective form of birth control with failure rates \<1% per year (e.g., implant, injectable, combined oral contraceptive, intrauterine contraceptive device, sexual abstinence, vasectomized partner) during participation in the study (and at least 3 months thereafter).
• Is not nursing.
• Patient's laboratory values (blood and urine) are within the range of normal or abnormal values are within normal levels for the disease and in the opinion of the PI the values are not clinically relevant for study participation.
• Patient is in good, general health and free of any known disease state or physical condition which, in the investigator's opinion, might impair evaluation of the EBS lesions or which exposes the subject to an unacceptable risk by study participation.

You may not qualify if:

• Patient's use of prior or concomitant medication or medical treatments/procedures:
• Any investigational drug or therapy within 30 days.
• Systemic steroidal therapy within 30 days.
• Topical steroidal therapy within 14 days (Note: inhaled and ophthalmic products containing steroids are allowed).
• Systemic antibiotic therapy within 7 days.
• Currently receiving chemotherapy or radiation.
• Surgery within the previous 2 weeks (except for minor surgery, cosmetic or dental procedures as determined by the investigator).
• Started to take chronic medications (NSAIDs, antihistamines, etc.) at least 30 days prior to starting study medication.
• Patient's medical history includes:
• Cancer that is currently undergoing treatment.
• History of chronic and severe vitamin, mineral, or protein deficiency.
• Current systemic infection.
• HIV/AIDS.
• Non-EBS skin disease (e.g., psoriasis, atopic dermatitis, eczema, sun damage, etc.), or condition (e.g., sunburn) that, in the opinion of the investigator, might put the patient at undue risk by study participation or interferes with the study medication application or the study assessments.
• An illness (e.g., neurological, cardiovascular, respiratory, hepatic, renal, or metabolic disease), condition, or situation that in the opinion of the principal investigator is likely to interfere with the patient's participation in or completion of the study.

Sponsors & Collaborators

• Northwestern University: collaborator
• BioMendics, LLC: lead
• Ann & Robert H Lurie Children's Hospital of Chicago: collaborator
• Stanford University: collaborator
• Lucile Packard Children's Hospital: collaborator

Study Sites (2)

Stanford University School of Medicine, Dermatology Department

Palo Alto, California, 94304, United States

RECRUITING

NU Dermatolgy CTU

Chicago, Illinois, 60611, United States

RECRUITING

Related Links

• BioMendics, LLC
• Stanford Medicine, Dermatology, Current EB Studies
• Northwestern Medicine, Department of Dermatology Clinical Trials

MeSH Terms

Conditions

Epidermolysis Bullosa Simplex; Epidermolysis Bullosa; Skin Diseases; Skin Abnormalities

Condition Hierarchy (Ancestors)

Congenital Abnormalities; Congenital, Hereditary, and Neonatal Diseases and Abnormalities; Skin Diseases, Genetic; Genetic Diseases, Inborn; Skin and Connective Tissue Diseases; Skin Diseases, Vesiculobullous

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Masking Details: Sponsor
• Purpose: TREATMENT
• Intervention Model: CROSSOVER
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Model Details: Part 1 of the study (2-months total) will involve a randomized, double-blinded treatment assignment model where one arm will receive active, and the other arm will receive placebo. Part 2 of the study (2-months total) will involve a single arm crossover where the placebo arm will crossover and receive active. The active arm will continue treating with active. During this part of the study the treatment labels will still be blinded.

Study Record Dates

• First Submitted: June 9, 2025
• First Posted: June 18, 2025
• Study Start: September 11, 2025
• Primary Completion (Estimated): January 1, 2027
• Study Completion (Estimated): September 1, 2027
• Last Updated: August 13, 2026

Record last verified: 2026-08

Data Sharing

• IPD Sharing: Will not share

Locations

US (2)